- Home
- DTSS vs LGVN Comparison
DTSS vs LGVN Comparison
Compare DTSS & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- LGVN
- Stock Information
- Founded
- DTSS 2014
- LGVN 2014
- Country
- DTSS China
- LGVN United States
- Employees
- DTSS N/A
- LGVN N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- DTSS Technology
- LGVN Health Care
- Exchange
- DTSS Nasdaq
- LGVN Nasdaq
- Market Cap
- DTSS 17.6M
- LGVN 16.4M
- IPO Year
- DTSS N/A
- LGVN 2021
- Fundamental
- Price
- DTSS $2.03
- LGVN $0.85
- Analyst Decision
- DTSS
- LGVN Strong Buy
- Analyst Count
- DTSS 0
- LGVN 2
- Target Price
- DTSS N/A
- LGVN $6.50
- AVG Volume (30 Days)
- DTSS 127.4K
- LGVN 329.0K
- Earning Date
- DTSS 11-12-2025
- LGVN 11-11-2025
- Dividend Yield
- DTSS N/A
- LGVN N/A
- EPS Growth
- DTSS N/A
- LGVN N/A
- EPS
- DTSS N/A
- LGVN N/A
- Revenue
- DTSS $71,616,820.00
- LGVN $2,073,000.00
- Revenue This Year
- DTSS N/A
- LGVN N/A
- Revenue Next Year
- DTSS N/A
- LGVN N/A
- P/E Ratio
- DTSS N/A
- LGVN N/A
- Revenue Growth
- DTSS 198.70
- LGVN 68.67
- 52 Week Low
- DTSS $1.63
- LGVN $0.63
- 52 Week High
- DTSS $3.10
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- DTSS 48.17
- LGVN 48.25
- Support Level
- DTSS $1.95
- LGVN $0.73
- Resistance Level
- DTSS $2.07
- LGVN $0.82
- Average True Range (ATR)
- DTSS 0.13
- LGVN 0.03
- MACD
- DTSS -0.02
- LGVN 0.02
- Stochastic Oscillator
- DTSS 23.08
- LGVN 94.35
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.